.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Daiichi Sankyo
UBS
Teva
Novartis
Merck
Argus Health
Boehringer Ingelheim
Moodys
Dow

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,943,788

« Back to Dashboard

Which drugs does patent 7,943,788 protect, and when does it expire?


Patent 7,943,788 protects INVOKAMET XR, INVOKAMET, and INVOKANA, and is included in three NDAs. There have been zero Paragraph IV challenges on Invokana and Invokamet

This patent has one hundred and fifty-seven patent family members in thirty-four countries.

Summary for Patent: 7,943,788

Title:Glucopyranoside compound
Abstract: A compound of the formula: ##STR00001## wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is --(CH.sub.2).sub.n-- (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.
Inventor(s): Nomura; Sumihiro (Kawaguchi, JP), Kawanishi; Eiji (Kitamoto, JP), Ueta; Kiichiro (Wako, JP)
Assignee: Mitsubishi Tanabe Pharma Corporation (Osaka-shi, JP)
Application Number:11/045,446
Patent Claim Types:
see list of patent claims
Compound; Composition; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Janssen PharmsINVOKAMET XRcanagliflozin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205879-002Sep 20, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY
Janssen PharmsINVOKAMET XRcanagliflozin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205879-001Sep 20, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY
Janssen PharmsINVOKAMET XRcanagliflozin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205879-004Sep 20, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY
Janssen PharmsINVOKAMET XRcanagliflozin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205879-003Sep 20, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY
Janssen PharmsINVOKAMETcanagliflozin; metformin hydrochlorideTABLET;ORAL204353-001Aug 8, 2014RXYesNo► Subscribe► Subscribe► SubscribeYY
Janssen PharmsINVOKAMETcanagliflozin; metformin hydrochlorideTABLET;ORAL204353-002Aug 8, 2014RXYesNo► Subscribe► Subscribe► SubscribeYY
Janssen PharmsINVOKAMETcanagliflozin; metformin hydrochlorideTABLET;ORAL204353-003Aug 8, 2014RXYesNo► Subscribe► Subscribe► SubscribeYY
Janssen PharmsINVOKAMETcanagliflozin; metformin hydrochlorideTABLET;ORAL204353-004Aug 8, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY
Janssen PharmsINVOKANAcanagliflozinTABLET;ORAL204042-001Mar 29, 2013RXYesNo► Subscribe► Subscribe► SubscribeYY
Janssen PharmsINVOKANAcanagliflozinTABLET;ORAL204042-002Mar 29, 2013RXYesYes► Subscribe► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,943,788

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,785,403Glucopyranoside compound► Subscribe
7,511,021Substituted indazole-O-glucosides► Subscribe
8,202,984Glucopyranoside compound► Subscribe
7,816,331Substituted indazole-O-glucosides► Subscribe
7,084,124Substituted indazole-O-glucosides► Subscribe
7,511,022Substituted indole-O-glucosides► Subscribe
7,820,630Substituted indole-O-glucosides► Subscribe
7,521,430N-glucoside compounds having an inhibitory activity against sodium-dependent glucose transporter► Subscribe
7,511,020Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides► Subscribe
7,129,220Substituted indole-O-glucosides► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,943,788

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine87991► Subscribe
Ukraine86599► Subscribe
Ukraine86042► Subscribe
Ukraine85569► Subscribe
Ukraine83377► Subscribe
Ukraine83243► Subscribe
Taiwan200526678► Subscribe
Taiwan200524951► Subscribe
Taiwan200524950► Subscribe
Taiwan200521131► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
AstraZeneca
Colorcon
Farmers Insurance
Dow
US Department of Justice
Cantor Fitzgerald
Accenture
Cerilliant
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot